Evogene Q3 Revenue Collapses to $141K After Bayer Deal Ends, Loss Widens
EVGN sits 29% above its 52-week low of $0.25.
Summary
Q3 revenue came in at $141,000 against a $365,000 consensus — a steep miss driven by the May 2026 conclusion of the Bayer license and collaboration agreement. The company swung to a net loss from prior-year net income, with R&D costs up on the absence of prior-year grants and FX, while sales and marketing fell on lower activity at Casterra and AgPlenus. The loss per share of $0.17 was slightly better than the $0.19 consensus, but that is small comfort against a revenue base that has largely evaporated. No financial or operational guidance was given. This lands on top of a rough stretch: the September 28 6-K showed a $7.7M H1 loss and a fully used $3.3M ATM, and the November 16 6-K disclosed chairman Nir Nimrodi's resignation. With the stock at $0.32 and a March 29, 2027 Nasdaq bid-price deadline, the balance sheet and any new financing terms matter more than the P&L line items.
At the time of this announcement, EVGN was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $0.25 to $1.26. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.